Twist Bioscience CEO Sells Shares for $1.12 Million Profit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 55 minutes ago
0mins
Source: Fool
- Insider Stock Transaction: Twist Bioscience CEO Emily Leproust exercised 16,470 options and sold the shares for approximately $1.12 million, indicating ongoing executive confidence in the company's stock performance.
- Shareholding Analysis: Post-transaction, Leproust holds 846,872 shares directly and has 538,218 employee stock options outstanding, reflecting significant ongoing financial exposure to future equity value.
- Strong Performance: As of May 31, 2026, Twist Bioscience shares delivered a total return of 128.23% over the past year, showcasing robust growth momentum in the synthetic biology sector.
- Revenue Outlook Upgrade: The company expects total revenue for fiscal 2026 to increase by 17% to 19%, reaching between $442 million and $447 million, highlighting strong demand for its DNA synthesis services and competitive market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TWST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TWST
Wall Street analysts forecast TWST stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 72.330
Low
39.00
Averages
41.25
High
43.00
Current: 72.330
Low
39.00
Averages
41.25
High
43.00
About TWST
Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Twist Bioscience CEO Sells Shares for $1.12 Million Profit
- Insider Stock Transaction: Twist Bioscience CEO Emily Leproust exercised 16,470 options and sold the shares for approximately $1.12 million, indicating ongoing executive confidence in the company's stock performance.
- Shareholding Analysis: Post-transaction, Leproust holds 846,872 shares directly and has 538,218 employee stock options outstanding, reflecting significant ongoing financial exposure to future equity value.
- Strong Performance: As of May 31, 2026, Twist Bioscience shares delivered a total return of 128.23% over the past year, showcasing robust growth momentum in the synthetic biology sector.
- Revenue Outlook Upgrade: The company expects total revenue for fiscal 2026 to increase by 17% to 19%, reaching between $442 million and $447 million, highlighting strong demand for its DNA synthesis services and competitive market position.
See More
Analysis of Twist Bioscience CEO's Stock Sale Transaction
- Stock Sale Overview: On May 28, 2026, Twist Bioscience CEO Emily Leproust exercised options to sell 16,470 shares of common stock for approximately $1.12 million, with the transaction value based on a weighted average purchase price of $67.91 from SEC Form 4, indicating high liquidity and market confidence.
- Ownership Change: This transaction reduced Leproust's direct holdings to 846,872 shares, representing a 1.91% decrease in her direct ownership, suggesting active trading by executives that may influence investor perceptions of corporate governance.
- Financial Performance Boost: Twist Bioscience reported a 28% year-over-year increase in sales from its DNA synthesis and protein solutions lab in Q2 of fiscal 2026, alongside a rise in gross margin to 51.6%, highlighting the company's strong growth potential in the synthetic biology sector.
- Optimistic Future Outlook: Management has raised the fiscal 2026 revenue outlook to between $442 million and $447 million, reflecting a growth rate of 17% to 19%, and expects to report positive adjusted EBITDA in Q4, indicating enhanced competitiveness and profitability in the market.
See More
Twist Bioscience Launches Complex Genes Product Line
- Product Line Expansion: On May 4, Twist Bioscience launched an early access version of 'Complex Genes,' which supports DNA sequences up to 7,000 base pairs, significantly enhancing gene length and structural complexity while meeting 99.5% of clonal gene orders and 99.9% of all DNA product demands, thereby strengthening the company's competitive position in the gene synthesis market.
- Market Demand Response: CEO Emily Leproust emphasized that researchers require partners capable of rapidly delivering complex genes at scale, and this expansion allows the company to accept a broader range of designs, thus shortening discovery timelines and further driving innovation in the biotech sector.
- Technical Support: The new capability supports AI-driven drug discovery and nucleic acid therapeutics, where precise synthesis of complex sequences is critical, indicating Twist Bioscience's strategic positioning in cutting-edge biotechnology.
- Global Operations: Twist Bioscience operates across the Americas, EMEA, and APAC, developing patented semiconductor-based synthetic DNA production techniques, showcasing its potential for global market expansion and technological innovation.
See More
TWIST BIOSCIENCE CORP: TD COWEN INCREASES TARGET PRICE FROM $58 TO $68
- Company Update: TWiST BioScience Corp has raised its target price significantly.
- New Target Price: The target price has increased from $58 to $68.
See More
Twist Bioscience Reports Strong Q2 Earnings with AI Growth
- Consistent Revenue Growth: Twist Bioscience achieved its 13th consecutive quarter of revenue growth, with Q2 revenue increasing 19.3% year-over-year to $110.7 million, demonstrating the company's strong performance and consistent execution in the market.
- Margin Expansion: The gross margin expanded to 51.6%, reflecting effective cost control and laying the groundwork for future profitability, with expectations to achieve adjusted EBITDA breakeven in Q4 of fiscal 2026.
- AI-Driven Drug Discovery: Revenue from DNA Synthesis and Protein Solutions grew by 28%, driven by the partnership with Amazon Web Services, indicating strong growth potential in AI-enabled drug discovery and further solidifying the company's market position.
- Optimistic Outlook: The company raised its fiscal 2026 revenue guidance to $442 million to $447 million, reflecting confidence in growth for the second half of the year, particularly in the NGS application area, which is expected to drive revenue growth back to 20%.
See More
Twist Bioscience Q2 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Twist Bioscience reported a Q2 GAAP EPS of -$0.71, missing estimates by $0.23, yet achieved revenue of $110.72 million, a 19.3% year-over-year increase, surpassing expectations by $3.06 million, indicating resilience in the market.
- DNA Synthesis and Protein Solutions: This segment saw a 28% year-over-year revenue growth to $53.3 million, with a 4% sequential increase, reflecting sustained demand and an increase in market share within the biotechnology sector.
- NGS Applications Growth: NGS revenue grew 12% year-over-year to $57.4 million, with a 9% sequential increase, showcasing the company's competitive edge and potential for future growth in genomics.
- Expanded Customer Base: The company shipped products to approximately 2,583 customers in Q2, up from 2,431 in the same period last year, demonstrating increased market acceptance and rising customer demand for its offerings.
See More
Twist Bioscience CEO Sells Shares for $1.12 Million Profit
- Insider Stock Transaction: Twist Bioscience CEO Emily Leproust exercised 16,470 options and sold the shares for approximately $1.12 million, indicating ongoing executive confidence in the company's stock performance.
- Shareholding Analysis: Post-transaction, Leproust holds 846,872 shares directly and has 538,218 employee stock options outstanding, reflecting significant ongoing financial exposure to future equity value.
- Strong Performance: As of May 31, 2026, Twist Bioscience shares delivered a total return of 128.23% over the past year, showcasing robust growth momentum in the synthetic biology sector.
- Revenue Outlook Upgrade: The company expects total revenue for fiscal 2026 to increase by 17% to 19%, reaching between $442 million and $447 million, highlighting strong demand for its DNA synthesis services and competitive market position.
See More
Analysis of Twist Bioscience CEO's Stock Sale Transaction
- Stock Sale Overview: On May 28, 2026, Twist Bioscience CEO Emily Leproust exercised options to sell 16,470 shares of common stock for approximately $1.12 million, with the transaction value based on a weighted average purchase price of $67.91 from SEC Form 4, indicating high liquidity and market confidence.
- Ownership Change: This transaction reduced Leproust's direct holdings to 846,872 shares, representing a 1.91% decrease in her direct ownership, suggesting active trading by executives that may influence investor perceptions of corporate governance.
- Financial Performance Boost: Twist Bioscience reported a 28% year-over-year increase in sales from its DNA synthesis and protein solutions lab in Q2 of fiscal 2026, alongside a rise in gross margin to 51.6%, highlighting the company's strong growth potential in the synthetic biology sector.
- Optimistic Future Outlook: Management has raised the fiscal 2026 revenue outlook to between $442 million and $447 million, reflecting a growth rate of 17% to 19%, and expects to report positive adjusted EBITDA in Q4, indicating enhanced competitiveness and profitability in the market.
See More
Twist Bioscience Launches Complex Genes Product Line
- Product Line Expansion: On May 4, Twist Bioscience launched an early access version of 'Complex Genes,' which supports DNA sequences up to 7,000 base pairs, significantly enhancing gene length and structural complexity while meeting 99.5% of clonal gene orders and 99.9% of all DNA product demands, thereby strengthening the company's competitive position in the gene synthesis market.
- Market Demand Response: CEO Emily Leproust emphasized that researchers require partners capable of rapidly delivering complex genes at scale, and this expansion allows the company to accept a broader range of designs, thus shortening discovery timelines and further driving innovation in the biotech sector.
- Technical Support: The new capability supports AI-driven drug discovery and nucleic acid therapeutics, where precise synthesis of complex sequences is critical, indicating Twist Bioscience's strategic positioning in cutting-edge biotechnology.
- Global Operations: Twist Bioscience operates across the Americas, EMEA, and APAC, developing patented semiconductor-based synthetic DNA production techniques, showcasing its potential for global market expansion and technological innovation.
See More
TWIST BIOSCIENCE CORP: TD COWEN INCREASES TARGET PRICE FROM $58 TO $68
- Company Update: TWiST BioScience Corp has raised its target price significantly.
- New Target Price: The target price has increased from $58 to $68.
See More
Twist Bioscience Reports Strong Q2 Earnings with AI Growth
- Consistent Revenue Growth: Twist Bioscience achieved its 13th consecutive quarter of revenue growth, with Q2 revenue increasing 19.3% year-over-year to $110.7 million, demonstrating the company's strong performance and consistent execution in the market.
- Margin Expansion: The gross margin expanded to 51.6%, reflecting effective cost control and laying the groundwork for future profitability, with expectations to achieve adjusted EBITDA breakeven in Q4 of fiscal 2026.
- AI-Driven Drug Discovery: Revenue from DNA Synthesis and Protein Solutions grew by 28%, driven by the partnership with Amazon Web Services, indicating strong growth potential in AI-enabled drug discovery and further solidifying the company's market position.
- Optimistic Outlook: The company raised its fiscal 2026 revenue guidance to $442 million to $447 million, reflecting confidence in growth for the second half of the year, particularly in the NGS application area, which is expected to drive revenue growth back to 20%.
See More
Twist Bioscience Q2 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Twist Bioscience reported a Q2 GAAP EPS of -$0.71, missing estimates by $0.23, yet achieved revenue of $110.72 million, a 19.3% year-over-year increase, surpassing expectations by $3.06 million, indicating resilience in the market.
- DNA Synthesis and Protein Solutions: This segment saw a 28% year-over-year revenue growth to $53.3 million, with a 4% sequential increase, reflecting sustained demand and an increase in market share within the biotechnology sector.
- NGS Applications Growth: NGS revenue grew 12% year-over-year to $57.4 million, with a 9% sequential increase, showcasing the company's competitive edge and potential for future growth in genomics.
- Expanded Customer Base: The company shipped products to approximately 2,583 customers in Q2, up from 2,431 in the same period last year, demonstrating increased market acceptance and rising customer demand for its offerings.
See More
